Search Results for: 19

Theriva™ Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

November 03, 2022 08:00 ET – Initiation of Cohort 2 Follows a Positive Review of Safety and Pharmacokinetic (PK) Data from Cohort 1 by an Independent Data and Safety Monitoring Committee – – Cohort 2 Patient Dosing Highlights Momentum Across the Theriva Oncology-Focused Clinical Pipeline – ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) — Theriva […]

Theriva™ Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Read More »

Theriva™ Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus Therapeutics

-Webinar to feature presentation from immunotherapy experts Michael Aaron Morse, M.D., and Arsen Osipov, M.D., on Monday, November 7th at 11 a.m. ET- October 31, 2022 08:00 ET ROCKVILLE, Md., Oct. 31, 2022 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat

Theriva™ Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus Therapeutics Read More »

Synthetic Biologics Rebrands as Theriva Biologics

Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administration October 12, 2022 08:00 ET ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN). The new name, logo and

Synthetic Biologics Rebrands as Theriva Biologics Read More »

Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma

September 30, 2022 08:00 ET Preclinical results demonstrated that topotecan treatment enhanced VCN-01 oncolytic activity against retinoblastoma ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the presentation of new data from

Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma Read More »

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

September 27, 2022 08:00 ET – The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 – ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Read More »

Disclaimer 

The information in this website contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended, on Theriva™ Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology

Disclaimer  Read More »

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a presentation of initial data from a

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck Read More »

Theriva Home

DELIVERING A NEW CLASS OF ONCOLYTIC VIRUS THERAPEUTICS ABOUT THERIVA™ Theriva is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies are designed to enable systemic delivery and have the potential to enhance current standard-of-care therapies, offering patients with difficult-to-treat

Theriva Home Read More »

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11,

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results Read More »